HZB coordinates European collaboration to develop active agents against Corona
The MX team at BESSY II specialises in analysing protein structures. This can also accelerate the development of drugs against COVID-19. © HZB
X-ray structure analysis at BESSY II enables the systematic testing of many thousands of molecules that could inhibit the reproduction and virulence of SARS-CoV2 viruses. Now, a team at HZB with partners from Austria and the Czech Republic has set up the NECESSITY project to investigate more than 8000 compounds in a high-throughput procedure and develop active agents against COVID-19.
The COVID-19 pandemic is far from over. Despite the rapid development of vaccines, it is not possible, for various reasons, to give everyone lasting protection through vaccination quickly enough. But so far, there are hardly any effective drugs for patients severely affected by COVID-19. Therapy is mainly limited to the administration of steroid drugs to control the immune reaction and artificial respiration.
Researchers around HZB-scientist Dr. Christian Feiler have initiated a three-party European research study termed NECESSITY, led by project partner Prof. Dr. Klaus Scheffzek (Med. University Innsbruck, Austria). Their goal is to investigate detailed interactions between Sars-CoV-2 proteins and chemical compounds developed and provided by Dr. Vladimír Kryštof (Palacký University Olomouc, the Czech Republic), using structural and biochemical approaches. X-ray structure analysis at BESSY II enables the systematic testing of many thousands of molecules that could inhibit the reproduction and virulence of SARS-CoV2 viruses. This research is funded by the Austrian Science Fund (FWF), the German Research Foundation (DFG), and the Czech Science Foundation (GACR).
At the light source BESSY II, which is operated by HZB, the structural analysis of macromolecules provides a fantastic tool to accelerate the development of effective substances against the SARS-CoV2 virus. The three-dimensional structure of the so-called viral main protease was determined at BESSY II for the first time at the beginning of 2020. This enzyme is indispensable for virus replication. However, it is not sufficient to investigate this one target, which is why several viral target proteins are being addressed in the NECESSITY project. The consortium will explore more than 8000 compounds at the MX-beamlines of BESSY II in a high-throughput procedure and identify substances from them that could dock to the main protease of SARS-CoV-2 or other target proteins. These drug-like candidates originate from a unique library generated and collected by Dr. Vladimír Kryštof, Palacký University Olomouc. All compounds are either already approved for the treatment of other diseases or are in various clinical phases. If hits were to come out of this, it would be possible to develop drugs against COVID-19 remarkably quickly. Prof. Dr. Klaus Scheffzek and his team at the Medical University in Innsbruck can investigate the hit compounds in detail using biophysical methods and initiate the first virological studies. Prof. Dr. Christian Drosten, Director of the Institute of Virology at Charité Berlin, and other experts are also on board as advisors and partners.
"In the NECESSITY project, we bring together expertise from different fields," says Feiler. "Together, we have planned a very efficient interdisciplinary workflow to identify antiviral substances that can be used as effective drugs against COVID-19 and beyond as quickly as possible."
The project is funded by the German Research Foundation and the corresponding funding organizations in Austria and the Czech Republic for 36 months with almost 800,000 Euros.
- The future of corals – what X-rays can tell usThis summer, it was all over the media. Driven by the climate crisis, the oceans have now also passed a critical point, the absorption of CO2 is making the oceans increasingly acidic. The shells of certain sea snails are already showing the first signs of damage. But also the skeleton structures of coral reefs are deteriorating in more acidic conditions. This is especially concerning given that corals are already suffering from marine heatwaves and pollution, which are leading to bleaching and finally to the death of entire reefs worldwide. But how exactly does ocean acidification affect reef structures?
Prof. Dr. Tali Mass, a marine biologist from the University of Haifa, Israel, is an expert on stony corals. Together with Prof. Dr. Paul Zaslansky, X-ray imaging expert from Charité Berlin, she investigated at BESSY II the skeleton formation in baby corals, raised under different pH conditions. Antonia Rötger spoke online with the two experts about the results of their recent study and the future of coral reefs.
- Susanne Nies appointed to EU advisory group on Green DealDr. Susanne Nies heads the Green Deal Ukraina project at HZB, which aims to support the development of a sustainable energy system in Ukraine. The energy expert has now also been appointed to the European Commission's scientific advisory group to comment on regulatory burdens in connection with the net-zero target (DG GROW).
- Long-term stability for perovskite solar cells: a big step forwardPerovskite solar cells are inexpensive to produce and generate a high amount of electric power per surface area. However, they are not yet stable enough, losing efficiency more rapidly than the silicon market standard. Now, an international team led by Prof. Dr. Antonio Abate has dramatically increased their stability by applying a novel coating to the interface between the surface of the perovskite and the top contact layer. This has even boosted efficiency to almost 27%, which represents the state-of-the-art. After 1,200 hours of continuous operation under standard illumination, no decrease in efficiency was observed. The study involved research teams from China, Italy, Switzerland and Germany and has been published in Nature Photonics.